NEW ORLEANS —Nancy Lurker, CEO and board director at EyePoint Pharmaceuticals, discusses topline results of the phase 1 DAVIO study of EYP-1901 for the treatment of wet age-related macular degeneration at the Eyecelerator meeting.
Uncategorized
VIDEO: EyePoint shares positive data from phase 1 topline results for wet-AMD treatment